Pfizer's Sutent wins US FDA's OK in rare pancreatic cancer
This article was originally published in Scrip
Executive Summary
The US FDA on 20 May gave its blessing to Pfizer's Sutent (sunitinib malate) as the first anti-vascular endothelial growth factor therapy available in the US to treat progressive, well-differentiated pancreatic neuroendocrine tumors (PNETs) in patients with unresectable locally advanced or metastatic disease.